2Sarah Czok ,Jenna R, Zechmeister, et al. Advanced endometrial canc- er: Is there a benefit to neoadjuvant therapy [ J ]. American Society of Clinical Oncology, 2012,30 ( 15 suppl) : 15548. 被引量：1
3Cohen C J, Brukner HW, Deppe G, et al. Multidrug treatment of ad- vanced and recurrent endometrial carcinoma:a Gynecologic Oncology Group study[J]. Obstetrics & Gynecology, 1984,63 (5) :719. 被引量：1
4Scarabell C, Campagnutta E, Giorda G, et al. Maxincal cytoreductive surgery as a reasonable therapeutical ternative for recurrent endometri- al carcinoma[ J]. Gynecol Onco1,1998,70( 1 ) :90. 被引量：1
6Barrett RJ, Blessing JA, Homesley HD, et al. Circadian-timed combi- nation of doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase Ⅱ study of the Gynecol Oncology Group [ J ]. Am J Clin 0nco1,1993,16(6) :494. 被引量：1
7Gargett CE, Chan RW, Schwab KE, et al. Hormone and growth factor signoting in endometrial renewal: role of stem/progenitor ceils [ J ]. Mol Cell Endecrinol,2008,288( 1 -2) :22. 被引量：1
8Helm CW, Toler CR, Martin RS 3rd,et al. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity[ J ]. Int J Gynecol Cancer, 2007,17 ( 1 ) :204 - 209. 被引量：1
9Morice P, Dubernard G, Rey A, et al. Results of interval debulking surgery in advanced stage ovarian cancer[J]. J Am Coil Surg, 2003, 197(6): 955-963. 被引量：1
10Fanfani F, Ferrandina G, Corrado G, et al. Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage Ⅲ c ovarian cancer patients[J].Oncology, 2003, 65(4), 316-322. 被引量：1
